Drug intelligence / Profile preview

mouse prostate-specific membrane antigen plasmid DNA vaccine

Development stage: Phase 1
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A vaccine consisting of a plasmid DNA encoding the murine prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing PSMA, resulting in decreased tumor growth. PSMA is a type 2 integral membrane glycoprotein abundantly expressed on the surface of prostate carcinomas and the neovasculature of most other solid tumors.

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on mouse prostate-specific membrane antigen plasmid DNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mouse prostate-specific membrane antigen plasmid DNA vaccine.

Explore the full profile